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Abstract
Infectious laryngotracheitis (ILT) is an acute and highly contagious respiratory disease of
chickens caused by an alphaherpesvirus, infectious laryngotracheitis virus (ILTV).
Recently, full genome sequences of wild-type and vaccine strains have been determined
worldwide, but none was from Europe. The aim of this study was to determine and analyse
the complete genome sequences of five ILTV strains. Sequences were also compared to
reveal the similarity of strains across time and to discriminate between wild-type and
vaccine strains. Genomes of three ILTV field isolates from outbreaks occurred in Italy in
1980, 2007 and 2011, and two commercial chicken embryo origin (CEO) vaccines were
sequenced using the 454 Life Sciences technology. The comparison with the Serva
genome showed that 35 open reading frames (ORFs) differed across the five genomes.
Overall, 54 single nucleotide polymorphisms (SNPs) and 27 amino acid differences in 19
ORFs and two insertions in the UL52 and ORFC genes were identified. Similarity among
the field strains and between the field and the vaccine strains ranged from 99.96% to
99.99%. Phylogenetic analysis revealed a close relationship among them, as well. This
study generated data on genomic variation among Italian ILTV strains revealing that, even
though the genetic variability of the genome is well conserved across time and between
wild-type and vaccine strains, some mutations may help in differentiating among them and
may be involved in ILTV virulence/attenuation. The results of this study can contribute to the
understanding of the molecular bases of ILTV pathogenicity and provide genetic markers to
differentiate between wild-type and vaccine strains.
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Introduction
Infectious laryngotracheitis (ILT) is an acute and highly contagious respiratory disease of
chickens caused by the Gallid herpesvirus 1 (GaHV-1), also called infectious laryngotracheitis
virus (ILTV) [1]. ILTV is classified as a member of the genus Iltovirus, subfamily Alphaherpes-
virinae, family Herpesviridae [2]. The virus has a linear dsDNA genome of about 150 kb com-
posed of a unique long (UL), a unique short (US) region, and inverted internal (IR) and
terminal (TR) repeats. The genome encodes 80 predicted viral protein open reading frames
(ORFs): 65 ORFs are located within the UL region and nine within the US region, while the
inverted repeats contain only three genes (ICP4, US10, and sORF4/3) [3].
Since its early appearance, several manifestations of ILT have been described associated
with mortality and/or decreased egg production and causing significant economic losses to the
poultry industry [1]. In commercial chicken flocks the disease is primarily controlled by vacci-
nation and several types of vaccines have been produced, including killed, live attenuated and
the recent recombinant vaccines [4]. Live attenuated vaccines are produced by sequential pas-
sages in tissue cultures (tissue culture origin, TCO) or embryonated eggs (chicken embryo ori-
gin, CEO) [1]. However, these vaccines may retain residual virulence and revert to virulence
after bird-to-bird passage resulting in disease in unprotected flocks [5, 6].
In the last decade, several molecular studies [7–18] have provided evidence that strains
identical or closely related to CEO vaccines have been involved in ILT outbreaks worldwide.
These observations have been recently strengthened by full genome sequence-based analyses,
which demonstrated that some reverted live attenuated vaccines were the main source of ILT
outbreaks [4, 6]. A total of 22 full DNA sequences of wild-type and vaccine strains from Aus-
tralia [3, 15, 19, 20], USA [16, 21, 22], and China [23] have been recently determined and are
currently available at the NCBI GenBank nucleotide database. Except for the European Serva
vaccine strain sequenced by an Australian research group [3], no full genome sequences of
European ILTV strains have been determined to date.
In Italy, epidemics of ILT have followed a cyclical pattern. One severe epidemic caused by
virulent ILTV strains occurred during the ‘80s [24]. Afterward, vaccination was introduced to
control the disease, and ILTV disappeared to re-emerge in 2007 when a second epidemic of
mild respiratory disease started to affect broiler flocks [25]. Currently, four ILT CEO vaccines
are licensed in Italy and only long-living birds (i.e. breeders and layers) are routinely vacci-
nated. In a previous study [25], PCR-RFLP and sequencing analysis of six genes (i.e. gE, gG,
TK, ICP4, ICP18.5, and ORFB-TK) suggested that some ILTV isolates involved in recent ILT
outbreaks in Italy might have been originated from CEO vaccines.
In this study, the full genome sequences of five Italian ILTV strains were determined using
the high throughput 454 Life Sciences sequencing technology. One field isolate from a histori-
cal case of ILT (1980), two field isolates from recent cases of ILT (2007 and 2011) and two
commercially available CEO vaccine viruses (Nobilis Laringovac1, MSD Animal Health and
Poulvac ILT1, Zoetis) were sequenced for analysing and comparing the genomes. The ulti-
mate goal of this study was to identify genetic variation among wild-type isolates from differ-
ent years and two distinct Italian epidemics of ILT, as well as between wild-type and vaccine
strains.
Materials and Methods
Virus
Five ILTV strains were sequenced: one field isolate from a historical case of ILT (1980 ILTV
field isolate, 4787/80), two field isolates from recent cases of ILT (2007 ILTV field isolate,
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193435/07, and 2011 ILTV field isolate, 757/11), and two commercially available ILTV CEO
vaccine viruses. The wild-type strains were isolated from unvaccinated chicken flocks affected
by ILT in 1980, 2007 and 2011. The 1980 and 2007 ILTV strains were isolated from tracheal tis-
sue propagated onto the chorioallantoic membrane (CAM) of SPF embryonated chicken eggs,
whereas the 2011 strain was obtained from a tracheal swab. The two ILTV CEO vaccines were
those commercialized in Italy as Nobilis Laringovac1 (MSD Animal Health S.r.l., Segrate [MI],
Italy) and Poulvac ILT1 (Zoetis Italia S.r.l., Roma, Italy), attenuated by sequential passages in
chicken embryos from the Serva and the Salsbury 146 strains, respectively.
Viral DNA Extraction
Total viral genomic DNA was extracted directly from the suspension of the inoculated CAMs,
the suspension of the tracheal swab and the reconstituted lyophilized vaccines using the High
Pure Viral Nucleic Acid Kit (Roche Diagnostics S.p.A, Roche Applied Science, Monza [MI],
Italy), according to the manufacturer’s instructions.
High Throughput Sequencing
Viral genomic DNAs were preliminarily amplified by a conventional PCR in order to enrich
the DNA by using the high fidelity Takara LA Taq™ DNA Polymerase (Lonza, Basel, Switzer-
land), allowing the generation of long and accurate PCR products. A set of about 10 kb overlap-
ping amplicons was obtained with the primers summarized in S1 Table. Afterward, a shotgun
sequencing approach was performed by using the GS Titanium Rapid Library Preparation Kit
(Roche). Briefly, amplicons from each viral strain were first pooled equimolarly, and then frag-
mented by nebulization (at 3 psi for 1 minute), purified, and ligated to adapter-tags with bar-
codes. DNA fragments were clonally amplified and multiplex sequencing was performed by
using the Roche 454 Life Sciences Genome Sequencer FLX platform (Roche 454 Life Sciences,
Branford, CT, USA), following the manufacturer’s instructions.
Sequencing Data Analysis
Images were processed using the runAnalysisPipe command provided with the DataProcessing
package (Roche). The resulting sequences were demultiplexed using the SFFtools suite (Roche)
and mapped to the ILTV reference sequence (Serva strain, GenBank accession no. HQ630064),
using the gsMapper tool provided with the instrument. The same tool was used to detect vari-
ants between the ILTV strains sequenced in the study and the reference sequence.
Whole Genome Finishing (Start/End)
The 5’ end of the ILTV genomes was amplified and sequenced with the Sanger method using a
pair of primers (Forward: AATTTCCACCGCGAAATGGC; Reverse: AACCGGGGTTTAGAGC
TGTG) designed to obtain a product of 1,292 bp. The 5’ and 3’ ends of the genomes were also
determined following the protocol described by Kong et al. [23], consisting of a single oligonu-
cleotide nested PCR (SON-PCR). Briefly, a single primer (GCGAGGTAGGGAGTGTGGCTGCTG)
was used for the first step of the SON-PCR, whereas the forward primer (GGTCGGACATGAA
ACCACAAGG) mapping at the 3’ end and the reverse primer (TGGGTGCTTGCCTGCATATACC)
mapping at the 5’ end of the genome were used for the nested PCR and sequencing.
The five Italian ILTV complete genomes were deposited in the NCBI GenBank database
under the accession numbers: KP677881 (4787/80 field isolate), KP677882 (193435/07 field
isolate), KP677883 (757/11 field isolate), KP677884 (MSD CEO vaccine) and KP677885 (Zoe-
tis CEO vaccine).
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IR/TR Variant Characterization
Since the ILTV internal repeat (IR) and terminal repeat (TR) are almost identical, it was not
possible to discriminate the reads from one region to those from the other one. To identify pos-
sible differences between the two regions, a modified version of the Serva genome (composed
only by UL, IR, and US) was used as reference for mapping. All reads of both IR and TR were
assembled and searched for variants with a consensus below 100% of the mapped reads, which
could indicate mutations present only in one of the repeat regions, and further analysed with
conventional PCR and Sanger sequencing. In particular, two couples of primers able to amplify
selectively the IR region, were designed and subsequently targeted to the selected variants with
nested PCRs (S2 Table). The detection of variants in the IR entailed their absence in the TR
and vice versa.
Alignment and Phylogenetic Analysis
Amultiple alignment including the five ILTV genomes and all the ILTV complete genomes
(except for the mosaic sequence of GaHV-1, accession number NC_006623) available in Gen-
Bank (Table 1) was built using ClustalW2 [26]. Similarly, the translated ORFs of all the genomes
were analysed. Phylogenetic trees of selected genes were constructed with Mega 6 [27] using the
Maximum Likelihood method based on the Tamura-Nei model [28].
Results and Discussion
Genome Organization
High throughput sequencing showed that the size of the five ILTV genomes ranged from
153,650 bp in the two vaccine strains to 153,653 bp in the 4787/80 field isolate and 153,662 bp
in the other two field isolates. On average, the G + C content of the genomes was 47.97% and a
total of 79 predicted ORFs was identified, according to the Serva reference sequence. A sum-
mary of the sequencing results, the full genome and genomic regions (UL, IR, US and TR)
lengths and the G + C content of the five strains is shown in Table 2. In Fig 1, the alignment
and the predicted ORFs arrangement of the five genomes with the Serva reference sequence are
shown.
Significant differences in the ILTV full genome lengths (ranging from 150,335 to 155,465
bp) have been reported [3, 15, 16, 19–23], with the extreme values due to large insertions/dele-
tions (INDELs), such as the deletion of about 3.3 kb at the 5’ end of the US TCO vaccines and
related field strains [16, 21]. Instead, differences in the genome length of the five strains
sequenced in this study did not involve large fragments of DNA. Accordingly with Spatz et al.
[21], a possible error in the assembly of the Serva reference genome was detected: a fragment of
1,016 bp was missing at the 3’ end of the TR region leading to an increase in the size of the
Serva genome from 152,630 to 153,645 bp. Additionally, the lack of this sequence fragment
was identified in the genomes of the Aus CEO vaccines (SA2 and A20), the Aus virulent strains
(ACC78 and CL9), and the US 1874C5 field strain.
Overall, the multiple amino acid sequence alignment showed that only 11 ORFs presented
different lengths among the ILTV genomes. Compared to the Serva reference sequence, differ-
ences in the coding regions of the five strains consisted of an insertion of nine nucleotides
(CCTCCTCTT, after nt position 1,892; Δ491GluGluGlu) in the UL52 gene of two field strains
(193435/07 and 757/11) and an insertion of three nucleotides (ATC, after nt position 813;
Δ66Asp) in the ORFC gene of the three field strains. The sequence alignment showed that the
insertion of three Glu in the UL52 gene was shared by the two Italian field strains and the Aus
V1-99 virulent strain. Notably, this insertion was located in a low complexity region rich of
Full Genomes of ILTV Strains from Italy
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CCT or CTT codons, suggesting a possible replication slippage event. The insertion in ORFC
was also present in the US 63140 isolate, a virulent strain closely related to CEO vaccines, in
the Aus CEO vaccines (SA2 and A20) and virulent strains (CL9 and CSW-1), and in the Chi
WG field strain. Both these mutations in UL52 and ORFC genes should be further investigated
in order to clarify their potential impact on viral biology and pathogenesis.
Table 1. Detailed information of the ILTV complete genomes published in GenBank (accessed 2015 November 5) used in the alignment and phylo-
genetic analyses.
GenBank accession
no.
Deﬁnition Size
(bp)
Virus strain Vaccine namea Country Reference
JX458823 GaHV-1 strain WG 153,505 Virulent WG - China -
JX458824 GaHV-1 strain K317 153,639 Virulent K317 - China -
JX458822 GaHV-1 strain LJS09 153,201 Virulent LJS09 - China Zhao et al., 2013
[48]
JX646898 GaHV-1 strain V1-99 153,630 Virulent V1-99 - Australia Lee et al., 2013
JX646899 GaHV-1 strain CSW-1 151,671 Virulent CSW-1 - Australia Lee et al., 2013
JN580317 GaHV-1 strain CEO low
passage
153,641 Vaccine Hudson Trachivax, Merck Animal
Health
America García et al., 2013b
JN580315 GaHV-1 strain TCO low
passage
155,465 Vaccine Unknown LT-IVAX, Merck Animal
Health
America García et al., 2013b
JN580313 GaHV-1 strain CEO TRVX 153,647 Vaccine Hudson Trachivax, Merck Animal
Health
America García et al., 2013b
JN580316 GaHV-1 strain CEO high
passage
153,647 Vaccine Hudson Trachivax, Merck Animal
Health
America García et al., 2013b
JN580314 GaHV-1 strain TCO high
passage
150,335 Vaccine Unknown LT-IVAX, Merck Animal
Health
America García et al., 2013b
JN580312 GaHV-1 strain TCO IVAX 155,465 Vaccine Unknown LT-IVAX, Merck Animal
Health
America García et al., 2013b
JN804827 GaHV-1 strain CL9 152,635 Virulent CL9 - Australia Lee et al., 2012
JN804826 GaHV-1 strain ACC78 152,632 Virulent ACC78 - Australia Lee et al., 2012
JQ083493 GaHV-1 strain vaccine LT
Blen
153,623 Vaccine Cover LT Blen, Merial America Chandra et al.,
2012
JQ083494 GaHV-1 strain vaccine
Laryngo Vac
153,624 Vaccine Hudson Laryngo-Vac, Zoetis America Chandra et al.,
2012
JN542535 GaHV-1 strain 81658 150,335 Virulent 81658 - America Spatz et al., 2012
JN542533 GaHV-1 strain 1874C5 149,682 Virulent 1874C5 - America Spatz et al., 2012
JN542536 GaHV-1 strain 63140/C/08/
BR
153,633 Virulent 63140/C/08/
BR
- America Spatz et al., 2012
JN542534 GaHV-1 strain USDA
reference
151,756 Virulent USDA - America Spatz et al., 2012
JN596963 GaHV-1 strain A20 152,978 Vaccine A20 Poulvac Laryngo A20,
Zoetis
Australia Lee et al., 2011b
JN596962 GaHV-1 strain SA2 152,975 Vaccine SA2 Poulvac Laryngo SA2,
Zoetis
Australia Lee et al., 2011b
HQ630064 GaHV-1 strain live
attenuated Serva
152,630 Vaccine Serva Nobilis ILT, MSD Australia Lee et al., 2011a
NC_006623b Gallid herpesvirus 1 148,687 - - - - Thureen & Keeler,
2006
a Data obtained from Menendez et al., 2014;
bSequence of ILTV assembled from 14 different published sequences.
This sequence was excluded from the multiple alignment and phylogenetic analyses.
doi:10.1371/journal.pone.0149529.t001
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Comparative Analysis
Comparative analysis between the five ILTV strains and the Serva reference sequence showed
that the nucleotide sequence identity ranged from 99.96% to 99.99%, with the lowest value
detected in the 193435/07 and 757/11 field isolates. The DNA sequence identity among the
wild-type strains and among the vaccine strains was 99.99% and 99.98%, respectively, whereas
that between them ranged from 99.97% to 99.98% (Table 3). All nucleotide and predicted
amino acid differences in the coding regions of the five strains compared to the Serva reference
sequence are presented in Table 4. Besides the two insertions identified in the UL52 and ORFC
genes, nucleotide differences were located in a total of 35 ORFs (including IR and TR variants).
The remaining 44 ORFs were completely conserved across the genomes. These findings are
consistent with previous studies reporting a pronounced genetic stability in ILTV [3, 16, 19–
22], according to the low mutation rate in members of the Alphaherpesvirinae subfamily [29].
The multiple amino acid sequence alignment showed that six ORFs were completely conserved
among the ILTV genomes. A 100% identity in ORFs of virulent, TCO and CEO vaccine strains
from distant geographical areas (i.e. USA, Australia and China) has been documented previ-
ously [16, 19, 20–23]. The conservation of genes in ILTV strains divergent for geographical
origin and virulence suggests that they may not be related to the virulence/attenuation of the
virus.
Comparing the three field isolates with the Serva reference sequence, a total of 38 SNPs and
two insertions were identified (Table 4). Eighteen SNPs were synonymous and 20 non-synony-
mous. Thirteen non-synonymous SNPs were found in all the three wild-type strains. Non-
Table 2. Results of the pyrosequencing run and genomic assembly (NCBI ILTV Serva reference sequence is reported for comparison).
Strain Number
of reads
Average
raw read
length
Coverage Total
genome
length
(bp)
UL (bp) IR (bp) US (bp) TR (bp) G + C
content
4787/80
ﬁeld
isolate
44,175 543.27a 156X 153,653 112,917
(1–112,917)
13,821
(112,918–126,738)
13,094
(126,739–139,832)
13,821
(139,833–153,653)
48.11%
193435/
07 ﬁeld
isolate
15,657 372.42 38X 153,662 112,926
(1–112,926)
13,821
(112,927–126,747)
13,094
(126,748–139,841)
13,821
(139,842–153,662)
48.1%
757/11
ﬁeld
isolate
26,867 376.86 66X 153,662 112,926
(1–112,926)
13,821
(112,927–126,747)
13,094
(126,748–139,841)
13,821
(139,842–153,662)
48.1%
MSD
CEO
vaccine
strain
22,433 377.86 55X 153,650 112,914
(1–112,914)
13,821
(112,915–126,735)
13,094
(126,736–139,829)
13,821
(139,830–153,650)
48.11%
Zoetis
CEO
vaccine
strain
53,001 385.71 133X 153,650 112,914
(1–112,914)
13,821
(112,915–126,735)
13,094
(126,736–139,829)
13,821
(139,830–153,650)
48.11%
Serva
vaccine
strain
- - - 153,645 112,915 13,818 13,094 13,818 48%
UL = unique long; IR = internal repeat; US = unique short; TR = terminal repeat; G + C = guanine + cytosine content.
aAverage read length is considerably higher for the strain 4787/80 because sequencing was conducted on a separate run, after the upgrade of the
instrument to FLX Plus.
doi:10.1371/journal.pone.0149529.t002
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synonymous SNPs in ORFF (T437C; Val146Ala) and US5 (A777G; Asp259Gly) were detected
only in the 4787/80 isolate; SNPs in UL21 (C1389A; Lys463Asp), sORF4/3-IR/TR (C434A;
Arg145Leu and G434T, Arg145Leu, respectively), and US6 (C401T; Ser134Leu) only in the
193435/07 and 757/11 isolates; and SNP in ICP4-TR (A2342G; His781Arg) only in the 4787/
Fig 1. Representation of the nucleotide and amino acid differences detected in the five ILTV genomes. The outermost, thick circle is the NCBI ILTV
reference sequence (Serva strain, GenBank accession no. HQ630064), where rectangles represent the coding sequences (CDS) and the colour code
indicates the transcription strand: cyan refers to CDS in the plus strand, orange stands for minus strand. The inner circles represent the five ILTV genomes
sequenced in this study (A = 4787/80, B = 193435/07, C = 757/11, D = MSDCEO vaccine, E = Zoetis CEO vaccine): on each circle, the blue bars indicate
silent nucleotide substitutions, while red ones highlight those causing amino acid substitutions. The yellow ribbons in the inner part of the figure connect the
coding sequences that are repeated in the ILTV genome. IR: internal repeat; TR: terminal repeat. The plot was obtained with Circos [44].
doi:10.1371/journal.pone.0149529.g001
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80 and 757/11 isolates. The comparison between the two vaccine strains and the Serva refer-
ence sequence revealed a total of 25 SNPs (Table 4). Eleven SNPs were synonymous and 14
non-synonymous. Three non-synonymous SNPs were detected in both the vaccine strains, as
well as in the three wild-type isolates. Three SNPs were unique to the MSD CEO vaccine strain,
while eight were detected only in the Zoetis CEO vaccine. SNPs in UL27, UL10, and US8 were
also present in the three wild-type strains, whereas the nucleotide substitution in ICP4-TR was
present only in two (4787/80 and 757/11) of the three field isolates. Notably, some non-synon-
ymous SNPs were present only in a portion of reads supporting the hypothesis of the existence
of viral subpopulations [16, 22]. Nucleotide and amino acid differences were also identified
between the two repeat regions (IR and TR) of the five strains (Table 4). To our knowledge, no
other studies have reported any difference between the IR and TR of ILTV genome.
In Table 5, amino acid differences in the coding regions of the five strains compared to the
complete ILTV genomes available in GenBank are summarized. Among 12 ILTV genes encod-
ing for surface glycoproteins [1], six (i.e. UL27, UL10, UL1, US5, US6, and US8 encoding for
gB, gM, gL, gJ, gD, and gE, respectively) revealed at least one amino acid change, and many of
these mutations were also present in other ILTV strains. Spatz et al. [21] suggested that muta-
tions in the surface glycoproteins gB, gM, gE and gL might have been caused by the different
geographical origin of the European Serva strain and the US virulent strains. Interestingly, we
found these mutations either in European ILTV field and CEO vaccine strains, including the
historical 4787/80 isolate. Therefore, mutations in the surface glycoproteins may not only have
been caused by the geographical pressure, but they may also be related to virulence/attenuation
of ILTV, given the important role these proteins play in host range and pathogenicity [30].
Besides the mutation Gln54Pro in the UL1 gene present in all the ILTV strains (except for the
Serva strain and the Chi WG and K317 strains), most of the mutations (i.e. UL27 Val116Ala,
UL10 Thr42Ala, and US8 Lys210Arg) were identified either in virulent and attenuated CEO
and TCO vaccine strains. Therefore, they do not seem to be useful for discriminating between
wild-type and vaccine ILTV strains. On the other hand, the mutation Ile644Thr in the UL27
gene was shared by all the virulent strains (except for the Chi LJS09 and K317) and lacking in
all the vaccine strains (except for the Aus SA2 and A20), as previously documented by García
et al. [16]. This mutation indeed appears to be a good marker for discriminating between field
and vaccine strains. It should be mentioned that glycoprotein B (encoded by the UL27 gene)
plays a fundamental role in herpesvirus attachment to target cells and cell entry [31]; then it
could affect viral tropism and infectivity. The mutations found in the US5 and US6 genes were
Table 3. Pairwise comparison of the five ILTV strains with the NCBI ILTV reference sequence (Serva strain) (global identity percentage and number
of identities over the genome length of the shortest of the two).
MSD CEO Zoetis CEO 193435/07 757/11 4787/80 Serva
strain
MSD CEO 100%
Zoetis
CEO
99.98% (153,625/
153,650)
100%
193435/07 99.97% (153,605/
153,650)
99.97% (153,610/
153,650)
100%
757/11 99.97% (153,603/
153,650)
99.97% (153,610/
153,650)
99.99% (153,660/
153,662)
100%
4787/80 99.97% (153,611/
153,650)
99.98% (153,619/
153,650)
99.99% (153,638/
153,653)
99.99% (153,638/
153,653)
100%
Serva
strain
99.98% (153,609/
153,645)
99.97% (153,606/
153,645)
99.96% (153,588/
153,645)
99.96% (153,586/
153,645)
99.97% (153,593/
153,645)
100%
doi:10.1371/journal.pone.0149529.t003
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Table 4. Summary of nucleotide and amino acid differences in the coding regions of the five ILTV strains vs the genome sequence of the NCBI
ILTV reference sequence (Serva strain).
Gene CDS Genomic
nt
position
Nt
substitution
(strand +)a
Field strainsb Vaccine strainsb
Name Product Nt
position
(strand +)
Nt
position
(coding
strand)
AA
position
4787/80 193435/
07
757/11 MSD
CEO
Zoetis
CEO
ORFF Protein IF 437 437 146 8,453 T! C V! A - - - -
UL54 Multifunctional
expression
regulator
199 1,437 479 10,844 T! C - - - I! M
(60%)
-
913 723 241 11,558 T! G - - - - E! D
1,235 401 134 11,880 C! T S! N S! N S! N - -
UL52 Helicase-primase
primase subunit
1,892 1,442 481 15,495 -!
CCTCCTCTT
- Q!
QEEE
Q!
QEEE
- -
UL50 Deoxyuridine
triphosphatase
799 453 151 18,490 A! G T! T T! T T! T - -
UL46 Tegument protein
VP11/12
849 849 283 22,496 A! G T! T T! T T! T - -
ORFA Protein IA 360 360 120 25,397 A! C S! S S! S S! S
(90.9%)
- -
465 465 155 25,502 C! T - V! V V! V
(94.6%)
- -
ORFB Protein IB 352 352 118 26,559 A! C R! R R! R R! R - -
744 744 248 26,951 T! C - - A! A - -
ORFC Protein IC 813 197 66 28,097 -! ATC D! DD
(90.3%)
D!
DD
D! DD - -
ORFE Protein IE 836 398 133 30,430 C! G G! A G! A G! A - -
1042 192 64 30,636 C! T - S! S S! S - -
UL23 Thymidine kinase 553 540 180 33,885 G! A D! D D! D D! D - -
UL27 Envelope
glycoprotein B
722 1931 644 39,573 A! G I! T I! T I! T - -
2306 347 116 41,157 A! G V! A V! A V! A - V! A
(95.1%)
UL28 DNA packaging
terminase
subunit 2
383 1913 638 41,857 A! G V! A V! A V! A V! A
(66.7%)
V! A
UL36 Large tegument
protein
413 7943 2648 55,613 C! T - - - R! H
(33.3%)
-
679 7677 2559 55,879 T! C T! T
(98.3%)
T! T T! T - -
2386 5970 1990 57,586 C! T - G! G G! G - -
4316 4040 1347 59,516 C! T R! H R! H R! H - -
7532 824 275 62,732 G! A - - - - A! V
(65.2%)
UL41 Tegument host
shutoff protein
832 369 123 72,697 A! G - - - R! R
(10.3%)
-
UL43 Envelope protein
UL43
369 369 123 75,044 T! C - - - F! F -
761 761 254 75,436 C! T - - - T! I
(36.8%)
-
UL44 Envelope
glycoprotein C
180 180 60 76,749 A! G - - E! E
(10.3%)
- -
(Continued)
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Table 4. (Continued)
Gene CDS Genomic
nt
position
Nt
substitution
(strand +)a
Field strainsb Vaccine strainsb
Name Product Nt
position
(strand +)
Nt
position
(coding
strand)
AA
position
4787/80 193435/
07
757/11 MSD
CEO
Zoetis
CEO
UL21 Tegument
protein UL21
211 1389 463 78,110 C! A - K! N K! N - -
UL19 Major capsid
protein
3870 3870 1291 84,421 C! T - L! L L! L - -
UL14 Tegument protein
UL14
459 459 153 90,940 A! G - - - - L! L
UL10 Envelope
glycoprotein M
1059 124 42 95,522 T! C T! A T! A T! A - T! A
(56%)
UL9 DNA replication
origin-binding
helicase
78 78 26 95,671 T! C - - - - P! P
UL5 Helicase-primase
helicase subunit
1027 1027 343 104,708 A! G K! E K! E K! E - -
UL1 Envelope
glycoprotein L
287 161 54 109,069 T! G Q! P Q! P Q! P Q! P Q! P
ICP4 Transcriptional
regulator ICP4
169 4281 1427 115,469 C! T G! G G! G G! G G! G G! G
2108 2342 781 117,408 T! C H! R H! R H! R H! R H! R
3460 990 330 118,760 T! C - - - - S! S
3778 672 224 119,078 T! C - - - - E! E
sORF4/
3
Protein sORF4/3 444 442 148 126,167 C! T A! T A! T A! T - -
452 434 145 126,175 C! A - R! L R! L - -
US2 Virion protein US2 289 402 134 127,028 G! A - F! F F! F - -
US3 Serine/threonine
protein kinase
US3
1200 1200 400 128,717 A! G G! G G! G G! G - -
UL47 Tegument protein
VP13/14
1812 1812 604 130,845 A! G - - - S! S
(47.6%)
-
US4 Envelope
glycoprotein G
33 33 11 131,101 C! T - - A! A
(16%)
- -
765 765 255 131,833 G! A - E! E - - -
US5 Envelope
glycoprotein J
777 777 259 132,933 T! C - - - I! I
(31.6%)
-
2345 2345 782 134,501 A! G D! G
(10%)
- - - -
US6 Envelope
glycoprotein D
401 401 134 135,322 C! T - S! L S! L - -
US8 Envelope
glycoprotein E
629 629 210 138,244 A! G K! R K! R K! R - K! R
sORF4/
3
Protein sORF4/3 307 307 103 140,259 C->T - - - P! S
(10.7%)
434 434 145 140,386 G->T - R! L R! L - -
442 442 148 140,394 G->A A! T A! T A! T - -
US10 Virion protein
US10
489 349 117 141,692 C->T - - - - A! T
(35.3%)
ICP4 Transcriptional
regulator ICP4
672 672 224 147,483 A->G - - - - E! E
(Continued)
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exclusive of the strains sequenced in this study and not reported previously. Notably, the muta-
tion in the US6 gene was shared only by the two recent field isolates (193435/07 and 757/11).
This gene encodes for the surface glycoprotein D that functions as receptor for herpesvirus and
ILTV binding and entry to susceptible cells [32, 33]. Additionally, this protein acts synergisti-
cally with the glycoprotein J (encoded by the US5 gene), which plays a key role in herpesvirus
infection by blocking the apoptotic cascade [34], affecting the virus ability to infect produc-
tively target cells.
Non-synonymous SNPs were found among genes encoding for viral enzymes, which play a
fundamental role during the replication cycle of herpesviruses by mediating the synthesis of
viral DNA [35]. Mutations were found in the UL28 gene encoding for the DNA packaging ter-
minase subunit 2, and the UL5 gene encoding for the helicase-primase helicase subunit. The
mutation in the UL5 gene was found mainly in field strains, appearing to be discriminating
between wild-type and vaccine strains, whereas that in the UL28 gene was found in most of the
ILTV strains including field, CEO and TCO vaccine strains. Additionally, an insertion in the
UL52 gene was uniquely identified in the two recent field isolates (193435/07 and 757/11) and
in the Aus V1-99 virulent strain. Together with the UL5 and UL8 genes, the UL52 gene
encodes for a component of the helicase-primase complex, which is essential for DNA replica-
tion fidelity of herpesviruses and thus for virus propagation [36]. Therefore, the biological sig-
nificance of such mutation requires further investigation in order to determine if it may be
involved in the genome stability and in the modulation of the virulence of the recent Italian
ILTV field strains.
Among genes encoding for ILTV transcriptional regulatory proteins, ICP4 and UL54
showed amino acid differences. In the ICP4 gene, only a single amino acid change was identi-
fied in the five genomes, and it was shared by most of the strains including field, CEO and
TCO vaccine strains. Among the three amino acid changes identified in the UL54 gene, the
Ile479Met was present only in the MSD CEO vaccine and the Glu241Asp only in the Zoetis
CEO vaccine. Similarly, Chandra et al. [22] found the same mutations in the LT-Blen and Lar-
yngo-Vac CEO vaccines and García et al. [16] in the Trachivax CEO vaccine. Interestingly, the
third mutation (Ser134Asn) was exclusive of the three field isolates sequenced in this study.
The UL54 gene encodes for the infected cell protein 27, a multifunctional regulatory protein
functioning in all stages of mRNA biogenesis from transcription, RNA processing and export
through translation [37]. Therefore, the Ser134Asn mutation could have an impact on the
efficiency of the viral replication cycle. In addition, it seems to be useful for discriminating
between the Italian field and vaccine strains.
Table 4. (Continued)
Gene CDS Genomic
nt
position
Nt
substitution
(strand +)a
Field strainsb Vaccine strainsb
Name Product Nt
position
(strand +)
Nt
position
(coding
strand)
AA
position
4787/80 193435/
07
757/11 MSD
CEO
Zoetis
CEO
2342 2342 781 149,153 A->G H! R - H! R - H! R
4281 4281 1427 151,092 G->A G! G G! G G! G - G! G
CDS = coding DNA sequence; Nt = nucleotide; AA = amino acid.
aNucleotide in the reference sequence (Serva strain);
bPredicted AA; Percentages indicate the amount of reads bearing the variant (not reported when 100%).
In bold non-synonymous nt substitutions.
doi:10.1371/journal.pone.0149529.t004
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Amino acid changes were also found in genes encoding for structural proteins, such as the
viral tegument proteins UL36 (large tegument protein) and UL21 (tegument protein UL21),
and encoding for the viral capsid protein UL43 (envelope protein UL43). Among all the muta-
tions detected in the UL36 gene, only the Arg1347His has been already described in the US
63140 field strain [16]. The UL36 gene encodes for the largest tegument protein of ILTV,
which has been demonstrated essential for virion assembly in herpesviruses, particularly for
the formation of structurally normal connections to the capsid in the initial stages of tegument
addition [38]. In this study, the mutation was identified in all the three ILTV field strains and
in other wild-type ILTV strains, appearing discriminating between field and vaccine strains. As
for the UL54 gene, the Ala275Val mutation was identified only in the Zoetis CEO vaccine
sequenced in this study and in the US Laryngo-Vac CEO vaccine sequenced by Chandra et al.
[22]. The mutation in the UL21 gene was exclusive of the two recent field strains (193435/07
and 757/11) and not reported previously. The UL21 gene encodes for a conserved protein of
the alphaherpesvirus tegument, essential for virus propagation and expressed during the early
and late stages of the replication cycle [39]. Tegument addition in herpesvirus morphogenesis
is a complex event involving several proteins. In addition, proteins of the tegument can have
regulatory or enzymatic activities. Mutations on these proteins can affect the efficiency of viral
assembly and the ability to produce an infective viral progeny [38, 39]. The mutation in the
UL43 gene was found exclusively in the MSD CEO vaccine and the Chi LJS09 field strain.
A number of non-synonymous SNPs and an insertion was found in the ORFF, ORFC,
ORFE, sORF4/3 and US10 genes, whose function is still unknown [1]. The ORFC and ORFE
genes are known to be unique genes of the members of the Iltovirus genus [30] and previous
studies carried out by Veits et al. [40] demonstrated that they are expressed during infection,
but not essential for ILTV replication. As for the insertion in the ORFC gene of the three field
strains, in the ORFE gene a mutation exclusive of these strains and the US 63140 isolate was
found. Our finding is in agreement with Spatz et al. [21] and García et al. [16], who suggested
that it may discriminate between the US 63140 CEO-related field strain and the US CEO vac-
cine strains and be involved in ILTV attenuation/virulence. In the ORFF gene, a single muta-
tion was found only in the 4787/80 strain and not in the other strains. Similarly to other genes
(i.e. UL54 and UL36), the mutation in the US10 gene was found only in the Zoetis CEO vaccine
sequenced in this study and in the US Laryngo-Vac CEO vaccine. The two mutations in the
sORF4/3 gene were present only in the Italian field strains: the Arg145Leu in all the three field
isolates, the Ala148Thr only in the two recent isolates (193435/07 and 757/11).
Although several mutations were identified only in field strains, allowing the possibility to
discriminate between field and vaccine strains in epidemiological studies, it is needed to clarify
their physiological function and their potential impact on ILTV biology to identify the genetic
determinants of ILT pathogenesis. In particular, it is essential the characterization of the func-
tion of the unique genes of the Iltovirus genus members that could play a key role on the modu-
lation of the virulence.
Interestingly, the two Italian CEO vaccines (MSD and Zoetis) were more closely related to
the US CEO vaccines than to the European Serva strain. In particular, the MSD CEO vaccine
was almost identical to the US LT-Blen and Trachivax CEO vaccines, and the Zoetis CEO vac-
cine to the US Laryngo-Vac CEO vaccine. This finding needs to be further investigated since
the Italian MSD CEO vaccine is reported to contain the Serva strain and the Italian Zoetis CEO
vaccine the Salsbury strain, whereas the US CEO vaccines are reported to contain the Hudson
strain (LT-Blen, Merial Select and Trachivax, Merck Animal Health) and the Cover strain (Lar-
yngo-Vac, Fort-Dodge Animal Health) [3, 16, 22].
Although a very high sequence identity among the five ILTV strains was detected, the most
relevant finding of this study was the pronounced genetic similarity (99.99%) between the
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historical field strain and the two recent field isolates (193435/07 and 757/11). The 4787/80
strain was isolated during a severe ILT outbreak occurred in the ‘80s when the vaccination
against ILT had not yet been introduced in Italy [24]. The other two strains were instead iso-
lated from outbreaks of ILT occurred recently (2007 and 2011, respectively) in unvaccinated
broiler flocks, showing mild clinical signs of the disease [25]. In a previous study [25], the
Authors postulated that the recent Italian ILT outbreaks were caused by strains closely related
to CEO vaccines based on the results of a multi-loci PCR-RFLP and sequencing of a number of
field isolates and CEO vaccines. Interestingly, analysis of partial sequences discriminated
between them. Most of the studies aimed at differentiating ILTV wild-type and vaccine strains
have been based on single- or multi-locus PCR-RFLP [10, 12, 13, 17, 41, 42] and sequencing
[11] or both [7–9]. More recently, full genome sequencing has been used to genotype ILTV,
but these studies are still very few [3, 15, 16, 19–23]. The genetic variation across the full
genome sequences indicated that the field strains were either closely related to CEO vaccines
and highly correlated each other, even though they derived from two distinct epidemics of ILT
occurred in a period spanning almost 30 years and with different ILT control programs imple-
mented by the Italian poultry industry. Therefore, we recommend that ILTV strain identifica-
tion should be based on full genome analysis.
Phylogenetic Analysis
Some of the genes with the highest variability among the ILTV complete genomes were selected
to perform phylogenetic analyses. According to Lee et al. [20] and to our data, we chose the
UL27, UL36, ICP4, and sORF4/3 genes: their nucleotide sequences, obtained from all the com-
plete ILTV genomes available in GenBank, were analysed with the Maximum Likelihood
method and the resulting trees are reported in Fig 2. In all cases, the Australian vaccine strains
SA2 and A20 clustered separately from the US and European genomes, with the only exception
represented by the virulent strain 1874C5 in the ICP4-related tree (Fig 2C). On the other hand,
the US and European CEO vaccines were always contained in a common cluster, which
included also other virulent ILTV strains from China (LJS09 and K317), Australia (ACC78),
and USA (63140). Also García et al. [16] and Menendez et al. [6] recognized a distinct phyloge-
netic group including CEO vaccines and the US 63140 strain, suggesting that this strain was a
revertant of CEO vaccines. As regards the genomes sequenced in this study, the Zoetis and
MSD vaccines clustered always with the other CEO vaccines, with the MSD showing a closer
relationship to the Serva strain, while the three field isolates 4787/80, 193435/07 and 757/11
grouped together (Fig 2B and 2D), even though separated by a quite long spanning time. Over-
all, this phylogenetic analysis suggests that the Italian field strains may be closely related to
CEO vaccines, even if the 4787/80 strain was isolated before the introduction of ILT vaccina-
tion in Italy.
In the last decade, molecular epidemiological studies have provided evidence that ILTV
strains identical or closely related to CEO (and to a lesser extent to TCO) vaccines in America,
Asia, Australia, and Europe [7–18] and ILTV strains originated by natural recombination of
CEO vaccines (i.e. Serva and SA2/A20 vaccine strains) in Australia [15, 20] have been the
cause of ILT outbreaks, even in regions of the world where live attenuated vaccines were not
used [9, 11, 12, 43].
In order to obtain a global representation of the relationships existing among the currently
known ILTV genomes, including the presence of recombinants, we generated a split network
with 18 full genomes (Fig 3). The network confirms the close relationship between the Italian
field strains and the CEO vaccines; nevertheless, the Italian isolates grouped together in a single
cluster, and a further split included also the US 63140 field strain. This result, together with the
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Fig 2. Evolutionary relationships of taxa. The evolutionary history was inferred using the Maximum Likelihood method based on the Tamura-Nei model
[28] on four different genes: UL27 (A), UL36 (B), ICP4 (C), and sORF4/3 (D). ILTV genomes sequenced in this study are highlighted in red (field strains) and
green (vaccine strains). The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown
next to the branches [45]. All positions containing gaps and missing data were eliminated. Evolutionary analyses were conducted in MEGA6 [27].
doi:10.1371/journal.pone.0149529.g002
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high sequence similarity existing between the historical Italian strain and the CEO vaccines,
suggests that an already existing CEO revertant ILTV strain could have been present in Italy at
that time and be the cause of the epidemic of the ‘80s. A recent study of Lee et al. [20] demon-
strated that the Australian CEO vaccine SA2 was very similar to ILTV strains isolated from
backyard flocks in the US, suggesting that this strain shared a common ancestor originated in
the American continent and subsequently introduced into Australia. Therefore, it is reasonable
to suppose that the precursor of the Italian ILTV wild-type strain might have been a CEO
revertant, perhaps introduced into Italy from the US.
Conclusions
This is the first study reporting the full genomic sequences of Italian ILTV field and vaccine
strains and providing valuable data about genomic variation of divergent ILTV strains from
a new geographical region, such as Europe. Several mutations were identified across the
genomes: some previously reported as associated with ILTV pathogenicity, some novel and
Fig 3. Split network showing reticulate evolutionary events of ILTV genomes. The network was obtained from the nucleotide sequences of Unique
Long, Internal Repeat and Unique Short regions of ILTV genome using SplitsTree4 [46] based on the neighbor-net method [47]. The Italian field strains (in
red) and the vaccine strains (in green) are closely related to the American CEO vaccines; in the zoomed inset, the split separating the field strains from all the
other genomes is highlighted in red, while the one grouping them to the American virulent strain 63140 is in blue.
doi:10.1371/journal.pone.0149529.g003
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exclusive of the Italian strains. The comparison of the genomes of wild-type strains isolated
during epidemics occurred across a quite long spanning time suggested that Italian ILT out-
breaks might have been related to a CEO revertant ILTV strain, maybe generated in the past.
Further studies are required to better define the molecular determinants associated with ILTV
virulence/attenuation and to individuate definitive markers associated with the virulence phe-
notypes, as well as to clarify the molecular epidemiology of ILT, recently challenged by the cir-
culation of strains originated from live attenuated vaccines, and to identify the origin of strains
circulating in poultry flocks.
Supporting Information
S1 Table. Primers designed for preliminary PCR of the five ILTV genomes. Nt = nucleotide;
Primers were designed on the NCBI ILTV reference sequence (Gallid Herpesvirus 1, GenBank
accession no. NC_006623).
(DOC)
S2 Table. Primers designed for PCR and sequencing of the IR and for nested PCR and
sequencing of the IR/TR variants of the five ILTV strains.
(DOC)
Author Contributions
Conceived and designed the experiments: AP EL GN EF CS. Performed the experiments: AP
GN EF AM PM. Analyzed the data: AP EL GN EF AM PM CS ST GP. Contributed reagents/
materials/analysis tools: AP AM PM CS ST GP. Wrote the paper: AP EL.
References
1. García M, Spatz S, Guy JS. Infectious Laryngotracheitis. In: Swayne DE, Glisson JR, McDougald LR,
Nolan LK, Suarez DL, Nair V, editors. Diseases of Poultry. Ames, USA: Iowa State Press; 2013a. pp.
161–179.
2. Davison AJ. Herpesvirus systematics. Vet Microbiol. 2010; 143: 52–69. doi: 10.1016/j.vetmic.2010.02.
014 PMID: 20346601
3. Lee SW, Markham PF, Markham JF, Petermann I, Noormohammadi AH, Browning GF, et al. First com-
plete genome sequence of infectious laryngotracheitis virus. BMCGenomics. 2011a; 12: 197.
4. Coppo MJ, Noormohammadi AH, Browning GF, Devlin JM. Challenges and recent advancements in
infectious laryngotracheitis virus vaccines. Avian Pathol. 2013; 42: 195–205. doi: 10.1080/03079457.
2013.800634 PMID: 23718807
5. Dufour-Zavala L. Epizootiology of infectious laryngotracheitis and presentation of an industry control
program. Avian Dis. 2008; 52: 1–7. PMID: 18459288
6. Menendez KR, García M, Spatz S, Tablante NL. Molecular epidemiology of infectious laryngotracheitis:
a review. Avian Pat. 2014; 43: 108–117.
7. Creelan JL, Calvert VM, Graham DA, McCullough SJ. Rapid detection and characterization from field
cases of infectious laryngotracheitis virus by real-time polymerase chain reaction and restriction frag-
ment length polymorphism. Avian Pathol. 2006; 35: 173–179. PMID: 16595312
8. Ojkic D, Swinton J, Vallieres M, Martin E, Shapiro J, Sanei B, et al. Characterization of field isolates of
infectious laryngotracheitis virus from Ontario. Avian Pathol. 2006; 35: 286–292. PMID: 16854641
9. Neff C, Sudler C, Hoop RK. Characterization of western European field isolates and vaccine strains of
avian infectious laryngotracheitis virus by restriction fragment length polymorphism and sequence anal-
ysis. Avian Dis. 2008; 52: 278–283. PMID: 18646457
10. Oldoni I, Rodriguez-Avila A, Riblet A, García M. Characterization of infectious laryngotracheitis virus
(ILTV) isolates from commercial poultry by polymerase chain reaction and restriction fragment length
polymorphism (PCR-RFLP). Avian Dis. 2008; 52: 59–63. PMID: 18459297
11. Chacón JL, Ferreira AJP. Differentiation of field isolates and vaccine strains of infectious laryngotra-
cheitis virus by DNA sequencing. Vaccine. 2009; 27: 6731–6738. doi: 10.1016/j.vaccine.2009.08.083
PMID: 19747995
Full Genomes of ILTV Strains from Italy
PLOS ONE | DOI:10.1371/journal.pone.0149529 February 18, 2016 17 / 19
12. Chacón JL, MizumaMY, Ferreira AJP. Characterization by restriction fragment length polymorphism
and sequence analysis of field and vaccine strains of infectious laryngotracheitis virus involved in
severe outbreaks. Avian Pathol. 2010; 39: 425–433. doi: 10.1080/03079457.2010.516386 PMID:
21154050
13. Blacker HP, Kirkpatrick NC, Rubite A, O’Rourke D, Noormohammadi AH. Epidemiology of recent out-
breaks of infectious laryngotracheitis in poultry in Australia. Aust Vet J. 2011; 89: 89–94.
14. Sadeghi M, Bozorgemehrifard MH, Keyvanfar H, Momtaz H, Shooshtari A, Charkhkar S. Differentiation
of field isolates and vaccine strains of infectious laryngotracheitis virus by DNA sequencing. Afr J Micro-
biol Res. 2011; 5: 4112–4117.
15. Lee SW, Markham PF, Coppo MJC, Legione AR, Markham JF, Noormohammadi AH, et al. Attenuated
vaccines can recombine to form virulent field viruses. Science. 2012; 337: 188. doi: 10.1126/science.
1217134 PMID: 22798607
16. García M, Volkening J, Riblet S, Spatz S. Genomic sequence analysis of the United States infectious
laryngotracheitis vaccine strains chicken embryo origin (CEO) and tissue culture origin (TCO). Virology.
2013b; 440: 64–74.
17. Kim HR, Kang MS, Kim MJ, Lee HS, Kwon YK. Restriction fragment length polymorphism analysis of
multiple genome regions of Korean isolates of infectious laryngotracheitis virus collected from chickens.
Poult Sci. 2013; 92: 2053–2058. doi: 10.3382/ps.2013-03134 PMID: 23873552
18. Shehata AA, Halami MY, Sultan HH, Abd El-Razik AG, Vahlenkamp TW. Chicken embryo origin-like
strains are responsible for Infectious laryngotracheitis virus outbreaks in Egyptian cross-bred broiler
chickens. Virus Genes. 2013; 46: 423–430. doi: 10.1007/s11262-012-0870-2 PMID: 23288626
19. Lee SW, Devlin JM, Markham JF, Noormohammadi AH, Browning GF, Ficorilli NP, et al. Comparative
analysis of the complete genome sequences of two Australian origin live attenuated vaccines of infec-
tious laryngotracheitis virus. Vaccine. 2011b; 29: 9583–9587.
20. Lee SW, Devlin JM, Markham JF, Noormohammadi AH, Browning GF, Ficorilli NP, et al. Phylogenetic
and molecular epidemiological studies reveal evidence of multiple past recombination events between
infectious laryngotracheitis viruses. PLoS ONE. 2013; 8: e55121. doi: 10.1371/journal.pone.0055121
PMID: 23383306
21. Spatz SJ, Volkening JD, Keeler CL, Kutish GF, Riblet SM, Boettger CM, et al. Comparative full genome
analysis of four infectious laryngotracheitis virus (Gallid herpesvirus-1) virulent isolates from the United
States. Virus Genes. 2012; 44: 273–285. doi: 10.1007/s11262-011-0696-3 PMID: 22173980
22. Chandra YG, Lee J, Kong BW. Genome sequence comparison of two United States live attenuated
vaccines of infectious laryngotracheitis virus (ILTV). Virus Genes. 2012; 44: 470–474. doi: 10.1007/
s11262-012-0728-7 PMID: 22382591
23. Kong C, Zhao Y, Cui X, Zhang X, Cui H, Xue M, et al. Complete genome sequence of the first Chinese
virulent infectious laryngotracheitis virus. PLoS One. 2013; 8: e70154. doi: 10.1371/journal.pone.
0070154 PMID: 23922947
24. Mandelli G, Vantellino G. La laringotracheite infettiva aviare. Rassegna sintetica. Riv Zoot Vet. 1981;
8: 328–345.
25. Moreno A, Piccirillo A, Mondin A, Morandini E, Gavazzi L, Cordioli P. Infectious Laryngotracheitis in Italy:
clinical cases, diagnosis and characterization by polymerase chain reaction—restriction fragment length
polymorphism (PCR-RFLP) and sequence analysis. Avian Dis. 2010; 54: 1172–1177. PMID: 21313836
26. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and
Clustal X version 2.0. Bioinformatics. 2007; 23: 2947–2948. PMID: 17846036
27. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Anal-
ysis version 6.0. Mol Biol Evol. 2013; 30: 2725–2729. doi: 10.1093/molbev/mst197 PMID: 24132122
28. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochon-
drial DNA in humans and chimpanzees. Mol Biol Evol. 1993; 10: 512–526. PMID: 8336541
29. Thiry E, Meurens F, Muylkens B, McVoy M, Gogev S, Thiry J, et al. Recombination in alphaherpes-
viruses. Rev Med Virol. 2005; 15: 89–103. PMID: 15546129
30. Thureen DR, Keeler CL Jr. Psittacid herpesvirus 1 and infectious laryngotracheitis virus: Comparative
genome sequence analysis of two avian alphaherpesviruses. J Virol. 2006; 80: 7863–7872. PMID:
16873243
31. Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. Fusing structure and function: a structural
view of the herpesvirus entry machinery. Nat Rev Microbiol. 2011; 9: 369–381. doi: 10.1038/
nrmicro2548 PMID: 21478902
32. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, Cohen GH. Herpes virus fusion
and entry: a story with many characters. Viruses. 2012; 4: 800–832. doi: 10.3390/v4050800 PMID:
22754650
Full Genomes of ILTV Strains from Italy
PLOS ONE | DOI:10.1371/journal.pone.0149529 February 18, 2016 18 / 19
33. Pavlova S, Veits J, Mettenleiter TC, FuchsW. Identification and functional analysis of membrane pro-
teins gD, gE, gI, and pUS9 of Infectious laryngotracheitis virus. Avian Dis. 2013; 57: 416–426. PMID:
23901755
34. Zhou G, Galvan V, Campadelli-Fiume G, Roizman B. Glycoprotein D or J delivered in trans blocks apo-
ptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing
both glycoproteins. J Virol. 2000; 74: 11782–11791. PMID: 11090178
35. Muylaert I, Tang KW, Elias P. Replication and recombination of herpes simplex virus DNA. J Biol
Chem. 2011; 286: 15619–15624. doi: 10.1074/jbc.R111.233981 PMID: 21362621
36. Weller SK, Kuchta RD. The DNA helicase-primase complex as a target for herpes viral infection. Expert
Opin Ther Targets. 2013; 17: 1119–1132. doi: 10.1517/14728222.2013.827663 PMID: 23930666
37. Sandri-Goldin RM. The many roles of the highly interactive HSV protein ICP27, a key regulator of infec-
tion. Future Microbiol. 2011; 6: 1261–1277. doi: 10.2217/fmb.11.119 PMID: 22082288
38. FanWH, Roberts AP, McElwee M, Bhella D, Rixon FJ, Lauder R. The large tegument protein pUL36 is
essential for formation of the capsid vertex-specific component at the capsid-tegument interface of her-
pes simplex virus 1. J Virol. 2015; 89: 1502–1511. doi: 10.1128/JVI.02887-14 PMID: 25410861
39. Le Sage V, Jung M, Alter JD, Wills EG, Johnston SM, Kawaguchi Y. The herpes simplex virus 2 UL21
protein is essential for virus propagation. J Virol. 2013; 87: 5904–5915. doi: 10.1128/JVI.03489-12
PMID: 23487471
40. Veits J, Mettenleiter TC, FuchsW. Five unique open reading frames of infectious laryngotracheitis virus
are expressed during infection but are dispensable for virus replication in cell culture. J Gen Virol. 2003;
84: 1415–1425. PMID: 12771409
41. Kirkpatrick NC, Mahmoudian A, O'Rourke D, Noormohammadi AH. Differentiation of infectious laryngo-
tracheitis virus isolates by restriction fragment length polymorphic analysis of polymerase chain reac-
tion products amplified frommultiple genes. Avian Dis. 2006; 50: 28–34. PMID: 16617977
42. Oldoni I, García M. Characterization of infectious laryngotracheitis virus isolates from the US by poly-
merase chain reaction and restriction fragment length polymorphism of multiple genome regions. Avian
Pathol. 2007; 36: 167–176. PMID: 17479379
43. Chacón JL, Núñez LF, Vejarano MP, Parra SH, Astolfi-Ferreira CS, Piantino Ferreira AJ. Persistence
and spreading of field and vaccine strains of infectious laryngotracheitis virus (ILTV) in vaccinated and
unvaccinated geographic regions, in Brazil. Trop Anim Health Prod. 2015; 47: 1101–1108. doi: 10.
1007/s11250-015-0834-3 PMID: 25904510
44. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aes-
thetic for comparative genomics. Genome Res. 2009; 19: 1639–1645. doi: 10.1101/gr.092759.109
PMID: 19541911
45. Felsenstein J. Confidence limits on phylogenies: An approach using the bootstrap. Evol. 1985; 39:
783–791.
46. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol. 2006;
23: 254–267. PMID: 16221896
47. Bryant D, Moulton V. Neighbor-net: an agglomerative method for the construction of phylogenetic net-
works. Mol Biol Evol. 2004; 21: 255–265. PMID: 14660700
48. Zhao Y, Kong C, Cui X, Cui H, Shi X, Zhang X, et al. Detection of infectious laryngotracheitis virus by
real-time PCR in naturally and experimentally infected chickens. PLoS One. 2013; 8: e67598. doi: 10.
1371/journal.pone.0067598 PMID: 23840745
Full Genomes of ILTV Strains from Italy
PLOS ONE | DOI:10.1371/journal.pone.0149529 February 18, 2016 19 / 19
